Partnering opportunity

More efficient method for preeclampsia treatment

Summary

A German university offers an improved approach to treat preeclampsia, a disease that can affect pregnant women. The vascular endothelial growth factor (VEGF)-multimer based apheresis is more efficient than conventional methods and results in shorter treatment duration. Partners from medical and pharmaceutical industry are sought for license agreements.

Partner sought

Partners from medical engineering and pharmaceutical industry with activities in gynecology are sought for license agreements. Within the cooperation the partners should support the further development and commercialise the invention.

Description

Preeclampsia is a potentially life-threatening multisystem disease affecting 4% to 8% of pregnant women after the 20th week of gestation (EGA - estimated gestational age). Around 20% of affected pregnancies have to be terminated before the 34th EGA. An excess of placental expressed anti-angiogenic soluble VEGF-receptor 1 sFlt-1 (Splice variant of VEGF-receptor 1: Soluble Fms-like thyrosinkinase-1) scavenges vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), causing generalized endothelial dysfunction. Interventions to restore the angiogenic balance in preeclamptic pregnancies are intensively studied and improve maternal and neonatal outcomes. Especially extracorporeal strategies to remove sFlt-1 are promising in human pregnancy. However, available apheresis systems adsorb sFlt-1 unspecifically and with low efficiency. Affinity enhanced ligands are needed to improve performance and compatibility of apheresis treatments. Researchers of a German university hospital have developed VEGF-based sFlt-1 capturing molecules (scVEGF165) characterised by higher affinity for sFlt-1 as compared to competing products and the ability to displace complexed endogenous VEGF and PlGF from its binding to sFlt-1 in patient blood. Thus the angiogenic balance is restored in double action, which will result in shorter treatment duration and more efficient sFlt-1 removal at low sFlt-1 plasma levels. For ex vivo characterisation, ligands were immobilized to biocompatible agarose matrix routinely used in medical aphersis systems. The university offers license agreements to medical engineering and pharmaceutical companies with an interest in the further development and implementation of the new method.

Advantages and innovations

There is strong interest in novel approaches with regard to extracorporeal therapies for preeclampsia. So far only one company is in the process of developing an antibody-based approach of sFlt-1 apheresis, which is less efficient as compared to this VEGF-based apheresis system. Specifically, the efficient liberation of endogenous VEGF and PlGF is an advantage of this novel approach: • Higher affinity for sFlt-1 as compared to competing products • Displace complexed endogenous VEGF and PlGF from its binding to sFlt-1 • Restoration of the angiogenic balance in double action

Development stage

Under development/lab tested

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company